| Primary Identifier | MGI:2388588 | Allele Type | Transgenic |
| Attribute String | Inserted expressed sequence | Gene | Tg(CD4-HIV)F27367Pjo |
| Strain of Origin | (C57BL/6 x C3H)F2 | Is Recombinase | false |
| Is Wild Type | false |
| description | Transgenic founder lines F26985, F27367, F27011, and F27372 were established. Disease latency was reflective of the level of transgene expression. The order of disease latency from shortest to longest time of onset is as follows: F27367 > F27011 > F27372 > F26985. Founder F26985 did not exhibit a phenotype. |
| molecularNote | Mouse CD4 enhancer sequences, the human CD4 promoter, 8.8 kb of HIV sequences, and an SV40 polyadenylation signal was used for the transgene. The promoter/enhancer sequences were used to drive transgene expression in CD4+ T cells and cells of the dendritic/macrophage lineage. The HIV sequence contained the following mutations: stop oligos (a 14-mer sequence introdicing stop codons in all 3 reading frames) in the gag, vif, rev, and env genes, a 22 bp deletion of the pol gene followed by a stop oligo, a deletion of nucleotides 5622-5737 in the vpr gene, a deletion of nucleotides 6062-6180 in the vpu gene, and a G to T nonsense mutation at nucleotide 5854 of the tat gene. Northern blot analysis showed high transgene expression in the thymus, moderate expression in lymph nodes, and weak expression in kidneys, lungs, intestines, and liver. |
